Cryo-Cell International, Inc. (CCEL) Q2 2026: Compliance Plan Accepted — Cautiously Optimistic

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) has received acceptance of its compliance plan from the NYSE American, a critical development for the company as it navigates financial challenges. The acceptance of the plan allows Cryo-Cell to continue trading on the NYSE American while working to address its compliance issues.

Key Findings:

• The NYSE American accepted Cryo-Cell's compliance plan on April 8, 2026, granting a compliance period through September 9, 2027.
• The company reported a stockholders’ deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years (ending November 30, 2023, November 30, 2024, and November 30, 2025).

Analyst View:

This quarter presents a mixed bag for shareholders. While the acceptance of the compliance plan is a positive step, the underlying financial issues remain concerning. The company has not demonstrated profitability in recent years, which raises questions about its long-term viability. The fact that it has until September 9, 2027, to regain compliance is a double-edged sword; it provides time to implement changes but also highlights the urgency of the situation.

Financial Metrics:

• Stockholders’ Deficit: Reported as of November 30, 2025.
• Net Losses: Reported in two of the three most recent fiscal years (November 30, 2023, and November 30, 2024).

Market Movements:

• The acceptance of the compliance plan allows Cryo-Cell's common stock to continue being listed and traded on the NYSE American, which is crucial for maintaining investor confidence.
• There is no mention of a dividend or share buyback program in the current update, indicating that the company may be conserving cash to address its financial challenges.

Forward-Looking Catalysts:

Investors should closely monitor Cryo-Cell's progress in executing its compliance plan over the next year. Key areas to watch include:

• The company's ability to improve its financial standing and reduce its stockholders’ deficit.
• Any updates on new initiatives or partnerships that could enhance revenue streams, particularly in the biopharmaceutical sector.
• Progress towards regaining compliance with NYSE American listing standards by the September 2027 deadline.

In summary, while the acceptance of the compliance plan is a positive development, shareholders should remain cautious given the company's ongoing financial struggles. The next quarter will be critical in determining whether Cryo-Cell can turn its fortunes around and regain investor confidence.

Based on the provided text, here are the extracted tables:

Note: The amounts in the following tables are in thousands.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

For the Years Ended November 30, 2025	For the Years Ended November 30, 2024	For the Years Ended November 30, 2023
xx	xx	xx
xx	xx	xx
xx	xx	xx
xx	xx	xx
xx	xx	xx
xx	xx	xx
xx	xx	xx
xx	xx	xx
xx	xx	xx

CONDENSED CONSOLIDATED BALANCE SHEETS

November 30, 2025	November 30, 2024
xx	xx
xx	xx
xx	xx
xx	xx
xx	xx
xx	xx
xx	xx
xx	xx
xx	xx

Feel free to reach out if you need any further assistance!

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.